IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Head-To-Head Studies Are Few, But Data Could Change Positioning
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
You may also be interested in...
Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.
Pfizer And J&J Settle Remicade Antitrust Litigation
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.